Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

icant differences were observed in the key efficacy endpoints between 876008 and placebo.

GSK has advanced a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II trial in patients with major depressive disorder. Enrollment of approximately 150 subjects is anticipated in this 6-week randomized, double-blind, placebo-controlled trial.

In addition to the two compounds listed above, GSK has also successfully completed a Phase I single dose-escalating clinical trial with a third CRF1 compound, 586529, for the treatment of anxiety and depression.

Urocortin 2 for Congestive Heart Failure (CHF) Completes Preclinical Evaluations

In December 2008 the Company completed two preclinical studies for urocortin 2 with favorable outcomes. The two GLP toxicology and safety assessment studies, over 14 days of continuous infusion, were completed in distinct species models, and confirmed the results of the two previous non-GLP studies. The favorable results of these studies should allow urocortin 2 to be infused for periods up to two weeks in duration in humans.

Vesicular Monoamine Transporter 2 Inhibitor (VMAT2)

VMAT2 is a protein concentrated in the human brain that is essential for the transmission of nerve impulses between neurons. The Company has identified a highly selective VMAT2 inhibitor that is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines thereby reducing the likelihood of "off target" side effects. This clinical candidate should be effective in the management of hyperkinetic movement disorders characterized by involuntary bodily movements as seen in patients suffering from Tardive Dyskinesia, and Huntington's disease. Additionally, the modulation of dopamine pathways may also be useful for patients suffering fro
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 Arizona ... inventors who want to develop their ideas into ... program. , The university is recruiting participants ... new “formation space” that provides early-stage entrepreneurs with ... AREA48 is open to anyone, ASU is particularly ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve ... the Creative Corridor region, is releasing results for its ... on Thursday, May 23rd at 10:30 a.m. The ... , The survey is a critical component to ... attract, nurture and retain people of diverse backgrounds, cultures ...
(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
(Date:5/21/2013)... 2013 The nation’s first trial involving ... nearing its conclusion in Washington state court, Bernstein Liebhard ... yesterday, an attorney for the Plaintiffs compared Intuitive Surgical ... tie sales and services for its customers. ... control of surgeons, to keep control of hospitals and ...
(Date:5/21/2013)... A new study appearing in the current ... cells harvested from fat (adipose) are more potent than ... the body’s immune system. , The finding could ... adipose tissue-derived stem cells (AT-SCs) are far more plentiful ... and can be collected from waste material from liposuction ...
Breaking Medicine News(10 mins):Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3
... simple as developing a taste for yerba mate tea? In ... colon cancer cells die when they are exposed to the ... this brew, which has long been consumed in South America ... tea not only induced death in human colon cancer cells, ...
... of Nebraska-Lincoln will lead a $25 million project to reduce ... coli strains that pose a major threat to public ... Food and Agriculture announced the grant at UNL on Monday, ... coli , or STEC, which cause more than 265,000 illnesses ...
... professor is turning to nutrition to tackle prostate cancer. ... make more informed diet decisions by studying foods and dietary ... cancer is one of the most common forms of cancer ... researching ways to prevent prostate cancer rather than how to ...
... discovered 13 new regions of the genome associated with the ... pathways involved in reproductive lifespan and will provide insights into ... disease. Menopause is a major hormonal change ... 50s. The timing of menopause can have a huge impact ...
... FRIDAY, Jan. 20 (HealthDay News) -- The number of people ... of the disorder is adopted by mental health experts later ... the changes will be, but they agree there will be ... the professionals who treat them. The changes could affect the ...
... patients treated for breast cancer is seriously compromised and ... menopause, a decrease in physical activity and weight gain, ... Comprehensive Cancer Center. , The study, published in the ... found that the mental issues faced by younger breast ...
Cached Medicine News:Health News:Compounds in mate tea induce death in colon cancer cells 2Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 2Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 3Health News:Eating smart: Researcher studies foods, dietary supplements that may reduce risk of prostate cancer 2Health News:Genes and timing of menopause 2Health News:Experts Weigh Changes to Definition of Autism 2Health News:Experts Weigh Changes to Definition of Autism 3Health News:Quality of life for younger breast cancer patients more adversely affected than older women 2Health News:Quality of life for younger breast cancer patients more adversely affected than older women 3
(Date:5/21/2013)... Calif. , May 21, 2013 ... and manufacture of wireless personal healthcare products and ... its reach, announcing the release of two new ... blood pressure monitors and scales: the Wireless Pulse ... (Photo: http://photos.prnewswire.com/prnh/20130521/SF17618 ) ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , ... NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today ... published online the positive Phase 2a study results ...  Dupilumab is an investigational monoclonal antibody targeting the alpha ... modulates signaling of both IL-4 and IL-13, drivers of ...
Breaking Medicine Technology:iHealth Lab adds new products and partners to mobile personal healthcare offering 2iHealth Lab adds new products and partners to mobile personal healthcare offering 3BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
... , Feb. 16 CalciMedica today announced that the ... No. 7,645,588, a composition patent involving STIM1, a key component of ... a cell comprising a STIM1 protein and an agent that modulates ... March 4, 2003 and was issued on January ...
... LAWRENCEVILLE, N.J. , Feb. 16 ... today that Wayne S. Mulcahy , Ph.D., has ... wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton ... products in ophthalmology and orphan diseases. , The ...
Cached Medicine Technology:CalciMedica Announces Issuance of US Patent No. 7,645,588, a Composition Patent Involving STIM1, a Key Component of the CRAC Channel 2Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: